# V54 Queue: Toward Halting MS Progression

Status: in-progress

V54 applies the mature toolkit to progression-specific, source-audited questions
without reopening the V41 public-data discovery boundary or weakening the
project's evidence standard.

## Timing

- Block start UTC: 2026-07-21T20:58:30Z
- Active target: 6h cumulative active time
- Projected target UTC if this interval stays continuous: 2026-07-22T02:58:30Z
- Active session intervals:
  - 2026-07-21T20:58:30Z - 2026-07-21T21:02:06Z (0h03m36s active)
  - 2026-07-21T21:02:06Z - OPEN
- Cumulative completed active runtime: 0h03m36s
- Wall-clock span: open

## Environment And Boundaries

- OpenGWAS authentication: POST-only checker passed HTTP 200 for `/gwasinfo`
  and `/tophits`; token expiry decoded locally as 2026-07-24 08:00 UTC.
- SAP AI Core health: Claude, Gemini, and RPT smoke-passed; AlphaFold and both
  structural/provenance gates remain available.
- Remote: `main` aligned with `origin/main` at block start (`5d538329`).
- V41 discovery-exhaustion boundary remains in force.
- V22/V42 locked rule and pre-registration remain immutable.
- Progression claims require source/batch audit before disease-stage or lesion
  localization is interpreted.

## Backlog

| item | status | note |
|---|---|---|
| Progression-data inventory and semantic contract | done | Seven datasets/packages audited; only cross-sectional PPMS-vs-SPMS and small-n lesion-state proxies are testable. No held transcriptomic dataset has longitudinal disability outcomes. |
| CD44/CXCR4 progressive-stage re-analysis | done | 44 source/tissue-compatible donors; 300k nulls. CD44/CXCR4 beta 0.343, CI -0.253 to 0.938, max-T p=0.787; same direction but inconclusive. No module passed the portable stage gate. |
| Frozen source/tissue-balanced stage-test plan | done | Amsterdam WM plus UK GM, donor-equal inference, five pre-existing modules, three-seed 300k null, BH plus max-T, and cross-source direction gate fixed before execution. |
| Smoldering-lesion / chronic-active microglia probe | done | Three exact active/inactive donor pairs plus 54 samples/21 donors and 300k wild nulls. No orthogonally supported module; receptor and lipid inconclusive, others not supported. |
| GSE279972 lysosomal morphology specificity audit | done | Fully adjusted beta 0.517, CI 0.199 to 0.834, wild p=0.00861, max-variant p=0.0453; all 21 LODO coefficients positive. Bounded foamy-morphology association only, not progression or target evidence. |
| Relapsing-to-progressive transition proxy audit | done | Seven datasets audited: 5 verified subject maps, 2 repeated transcriptomes, but 0 time-varying stage and 0 repeated disability/conversion. Transition is not identifiable; this is not a biological null. |
| Progression-specific module panel | done | No orthogonally supported module. OXPHOS is lower in foamy morphology (max-module p=0.0357) but direction-discordant across chronic-active pairs; resolution and MOCCI are inconclusive. |
| OXPHOS-versus-lysosomal foamy-state coupling sensitivity | done | Both survive mutual adjustment: OXPHOS beta -0.562, max-endpoint p=0.0114; lysosomal beta 0.463, max-endpoint p=0.0518; all LODO directions stable. Morphology-only. |
| CNS-intrinsic versus peripheral APC separation | done | No eligible compartment pair. GSE228330 baseline has RRMS n=10/SPMS n=5 and subtype/activity confounding (Fisher p=0.01698), plus no verified map, processed matrix, batch/composition, or disability. Localization is not identifiable, not a peripheral null. |
| Progression intervention-direction map | done | Sequential audit of 9 states: 0 pass the progression-specific gate, 0 target revisits. V53 context supplies 0 replicated selective control nodes, 0 additive-pair passes, and 0 consensus causal orientations. |
| AlphaFold progression-axis context | done | Not eligible: no candidate reached progression association, pathogenic direction, causal specificity, and selective perturbation gates. Structure was deliberately not used as target decoration. |
| Multi-lineage adversarial progression review | done | All 12 objections grounded. Two changed the morphology evidential grade; zero changed progression/target verdicts. Independent lenses added value through a real downgrade, not a new positive lead. |
| Macnair source-by-stage interaction review check | done | Five modules, 44 donors, 300k reduced-model wild nulls. No interaction passes. CD44/CXCR4 source effects are nearly equal but imprecise; lysosomal heterogeneity is inconclusive. |
| Global post-result morphology multiplicity audit | done | Holm across all 12 sequential follow-up tests. Only a partial resident-adjusted variant passes; fully adjusted lysosomal and both mutual-adjustment endpoints fail. Claim-level morphology wording downgraded to exploratory. |
| Foamy donor/lesion estimand and influence audit | done | Only 6/21 donors and 3/43 donor-lesion blocks vary in morphology. Donor-FE OXPHOS is direction-retained but null/unstable; lysosomal reverses near zero. Pooled inference is substantially between-donor or unresolved. |
| Progression power calibration and assumption audit | done | Null calibration acceptable: maximum 0.060 has Wilson 0.049-0.073, no lower bound >0.05, 48-cell reference max-tail p=0.895. Label-noise sensitivity completed without empirical-MS interpretation. |
| Multi-lineage objection disposition table | done | Complete artifact-traced table and four agreement clusters committed; model assertions remain proposal-only external records. |
| Progression-cohort acquisition specification | done | Three-role contract (longitudinal progression, paired compartment, functional direction) with 64 unique required fields and fail-closed intake actions. No powered sample size inferred from held data. |
| Progression package eligibility validator | done | Six synthetic role fixtures: 3 complete P1/P2/P3 pass, 3 malformed packages fail closed. Real source paths must exist; pass means inventory-ready only. |
| Progression-event power design skeleton | done | 288k synthetic cohorts/3 seeds/192 cells; null FPR median 0.043, max 0.060. Only 7/24 non-null scenarios reached 80%; OR 1.25/1.5 not by n=240. Assumption-labeled, not empirical. |
| Progression power label-noise sensitivity | done | 576k additional synthetic cohorts. Scenarios reaching 80% fall 7/24 -> 4/24 -> 3/24 at 0/5/10% symmetric label error; endpoint adjudication is a hard design requirement. |
| Progression power covariate/event-time extension | done | 90k synthetic cohorts/180k route evaluations. Stratified null median 0.046/max 0.0653 (40-cell max-tail 0.776); deliberate-confounding unadjusted null median 0.0887/max 0.1907. PHReg reference check passes. |
| Progression P1/P2 blinded preregistration template | done | Frozen process contract covers endpoint/timepoint, censoring, covariates, P2 interaction, missingness, multiplicity, and pass/fail/inconclusive semantics before score access. |
| Progression validator malformed-input expansion | done | Eight synthetic malformed/path fixtures added. They exposed and fixed a bug where nonexistent source paths were logged but did not fail `field_gate_pass`; all 14 total regressions now pass. |
| Progression outcome semantic checker | done | Twelve synthetic declarations: valid CDP/PIRA/P2 pass; nine proxy, incomplete, unconfirmed, or unblinded declarations fail closed. Method behavior only. |
| Joint foamy-state lesion-stratum transport sensitivity | done | Classes 2/3 eligible; NAWM ineligible (4 foamy donors). Neither endpoint passes within-stratum family gates; OXPHOS same-direction but imprecise, lysosomal reverses in class 2. Pooled state is not stratum-portable. |
| Foamy morphology-by-lesion heterogeneity test | done | Direct class-3-minus-class-2 interactions: OXPHOS beta 0.115, max-family p=0.940; lysosomal beta 0.004, p=1.000; LODO signs unstable. No heterogeneity support, but wide CIs do not establish homogeneity. |
| GSE228330 progression metadata request addendum | done | Ready-unsent 29-field addendum requests subject map, a/s definition, age, disability/PIRA components, relapse/steroid/treatment, MRI, composition, batch/QC, and matrix. Context-only unless full role gate passes. |
| V37 progression evidence-grade delta | done | Artifact-checked 18-item delta: 12 V37 items carried, 6 post-V37 additions; 2 method-strengthened, 3 progression-narrowed, 1 negative reinforced, and no target/progression promotion. |
| Combined P1/P2 intake gate orchestrator | done | Nine synthetic cross-gate fixtures pass: valid P1/P2 and additive metadata accepted; component failures, role/endpoint/package mismatch, and prior score access fail closed. |
| P2 compartment-interaction power design | done | 288k synthetic cohorts/576k route evaluations. Direct interaction is calibrated with perfect composition, or noisy composition when no imbalance exists; noisy adjustment under true imbalance remains invalid. Trusted adjusted scenarios reach 80% in 27/36 cells; independent OLS reference check passes. |
| Event-time assumption robustness | done | 225k synthetic cohorts/675k window evaluations. Four censoring families calibrate; joint score/event-risk censoring is invalid (null median 0.544, max 0.795, all spurious-negative). Crossing effects are detected only 0.127-0.157 overall at n=320/event=0.30 despite opposite window recovery. Four numerical references pass. |
| Progression endpoint adjudication fixtures | done | Sixteen synthetic CDP/PIRA fixtures pass: confirmed, transient, later-valid onset, missing/mistimed confirmation, relapse/steroid exclusion, component discordance, switch censoring, invalid baseline, duplicate day, malformed values, and unknown endpoint. CDP/PIRA remain distinct. |
| Progression cohort candidate role matrix | done | Ten known candidates checked from committed metadata: 0 P1, 0 P2, 0 P3. Gafson/Karolinska remain monitoring routes; GSE24427 is longitudinal but lacks repeated disability; no compartment pair or progression-qualified perturbation exists. |
| Event-time receipt diagnostics contract | done | Additive blind metadata gate requires complete censoring dates/reasons, source-treatment strata, IPCW/worst-case/joint-dependence sensitivities, and time-variation diagnostics. Eight synthetic fixtures pass expected fail-closed behavior. |
| P2 composition measurement acceptance contract | done | Direct linked measurements pass eligibility; proxies require a blinded direct-reference subset, reported reliability, rerun null calibration, and sensitivity-only interpretation. Expression-derived proxy alone fails. Nine synthetic fixtures pass. |
| V54 consolidated regression suite | done | One command runs 29 executable checks and 147 artifact/claim invariants; all pass. It pins method boundaries, endpoint fixtures, full intake-to-lock composition, ascertainment, negative-control, confirmation-error, and per-site precision boundaries, the hash-bound manifest, acquisition priorities/request packet, weaker-effect power, harmonization/calibration, planning, routing, switch estimands/gate, nonlinear-model checks/gate, and the design reference. |
| Competing-risk/death robustness | done | 129,600 seeded synthetic cohorts. Ordinary score- or progression-risk-dependent death calibrated, independent death had a strict-cell flag but was family-compatible and excluded from power, while joint score/progression-risk death was invalid (null max 0.119, predominantly false protective). Only 4/10 calibrated non-null scenarios reached 80%. |
| Visit-schedule interval-censoring audit | done | 172,800 seeded cohorts/691,200 route evaluations. Complete and independent-missing schedules calibrate; score-dependent and joint score/risk attendance are invalid (null maxima 0.158/0.165, false protective). Only complete quarterly visits at event probability 0.30 reach 80% by n=320 (2 route variants of 24 scenarios). |
| Repeated molecular-state reliability design | done | 216,000 seeded cohorts. Zero plan is method-invalid, but four have strict-cell/family-compatible flags and are excluded. Only low starting reliability (0.40) yields material repeat gains: 16/96 cells across k2 independent, k3 independent, and selected k3 correlated-error settings. High-reliability repeats do not clear all gates. |
| Multi-site progression transportability design | done | 115,200 seeded cohorts. Pooled inference is invalid in both hazard-aligned-score families (null maxima 0.685/0.482); all site-stratified families calibrate. Only n=450, event probability 0.30, balanced allocation passes full transport (2/24 score-structure variants); 60/30/10 allocation misses. |
| Prospective progression cohort design synthesis | done | Rerunnable 16-requirement/14-source synthesis separates the n=450/balanced/30%-event/quarterly stress-tested reference from a universal minimum and binds endpoint, attendance, competing-risk, reliability, site, P2, and therapeutic boundaries. Zero known P1 cohorts remains explicit. |
| Endpoint adjudicator malformed-input expansion | done | Five added fixtures bring the suite to 16/16. Duplicate day, malformed component/day, and unknown endpoint return INVALID_INPUT; later valid onset after a transient candidate is found at day 300 and confirmed at day 480. |
| Multi-site score-scale harmonization | done | 129,600 cohorts/259,200 routes; zero invalid null families. Six of 36 comparisons show material gain, all under severe 0.5/1/2 site scaling. Balanced n=450/event 0.30 improves transport 0.466 -> 0.809; imbalanced correction remains below readiness. Reversed-effect false transport max 0.0325. |
| Enrollment inflation and analyzable-event design | done | 122,805,000 synthetic replicates. Conditional gross totals are 690 at 10% losses/event 0.30, 990 at 20% losses/event 0.30, and 1,380 at 10% losses/event 0.15; no universal N claimed. |
| Blinded progression feasibility calculator | done | Nine synthetic routes pass expected decisions: two reference-aligned, four valid-but-below-reference, and three fail closed; actual upstream JSON and package binding are required. |
| Blinded information-accrual monitor | done | Ten synthetic routes: 3 continue, 1 metadata hold, 1 information lock, 5 fail closed. Effect direction/p-values/individual outcomes and efficacy/futility stopping are forbidden. |
| Treatment-switch estimand sensitivity | done | 72,000 cohorts/144,000 routes. Joint score/risk switching invalidates both estimands; score-dependent switching invalidates treatment policy. Two independent families are strict-cell/family-compatible and excluded. |
| Linear-effect misspecification audit | done | 18,000 disjoint calibration + 108,000 evaluation cohorts; 0/5 invalid null families. Only U-shaped crossing at n320 meets the material-miss rule (linear 0.105 vs omnibus 0.891); design warning only. |
| Progression score/site calibration receipt gate | done | Ten synthetic declarations pass expected decisions; six unsafe routes fail closed. Differing scales require blind within-site scaling; imbalance is processable but remains outside the tested transport reference. |
| Treatment-switch estimand receipt gate | done | Ten synthetic declarations pass expected routes: 2 process-ready and 8 fail closed; one frozen primary plus opposite sensitivity and complete switch metadata are mandatory. |
| Nonlinear diagnostic preregistration gate | done | Ten synthetic declarations verify the exact threshold/saturation/quadratic family, blind freeze, corrected alpha or disjoint calibration, and non-rescuing status; 2 pass and 8 fail closed. |
| Combined ascertainment adversarial stack | done | Primary 288k cohorts/576k routes suggested marginal compounding; independent 144k confirmation showed attendance weak-joint itself invalid. Unique compounding is not confirmed; joint score/risk attendance remains unsafe. |
| Progression reference-design machine manifest | done | Eight gates and 18 source artifacts are SHA-256-bound into one lifecycle/reference contract; verify mode and a threshold-tamper regression pass. |
| Progression acquisition value-of-information synthesis | done | Nine artifact-bound bundles: 5 immediate and 4 conditional. P1 longitudinal core + ascertainment provenance rank first; P2/P3 remain dependency-blocked. |
| Full synthetic P1 intake-to-lock dry run | done | Actual seven-stage validators compose over one package ID: 1 synthetic route locks, 1 continues blinded accrual, and 8 stage/cross-stage faults fail closed. |
| Weaker-effect progression cohort-size extension | done | 90k cohorts; null calibrated. HR1.2 not reached by 1,500; HR1.3 needs 900 at 30% events or 1,500 at 15%; HR1.5 needs 450/600. Conditional only. |
| Endpoint-confirmation error sensitivity | done | 230,400 cohorts; four families calibrate and four score-linked/joint families are invalid. Score-linked confirmation is a fail-closed inference boundary, not power loss. |
| Leave-site-out precision design | done | 96,000 cohorts; no design reaches strict every-site-CI readiness. Best HR1.5 n1,500/30%/balanced is 0.740 (minimum seed 0.735) despite sign transport 0.950. |
| Upper-range per-site precision extension | done | 72,000 cohorts. HR1.5/30% balanced first passes at n1,800 (weak-site median 102 events); imbalance passes at n3,000. HR1.3 and 15%-event routes do not pass through n3,000. |
| Acquisition request packet | done | Ready-to-send generic request plus 66-field provider template: 50 canonical P1/all-role, 12 immediate VOI additions, 4 confirmation-process fields; 51 gate-critical rows first. |
| Progression negative-control specification | done | Seven exact controls; one valid synthetic declaration passes and nine missing/post-hoc/rescuing/action-altered routes fail closed. Clean controls cannot upgrade the primary. |
| Progression external-review brief | todo | Produce a skeptic-facing summary of what would falsify the progression route and why current evidence does not imply a target. |
| Cumulative V54 progression report | todo | Maintain `docs/history/PROGRESSION_FRONTIER_V54.md` with supported/null/inconclusive outcomes and no target inflation. |
| V54 regression, provenance, structure, size, RAG, and clean close | todo | Run all gates, rebuild retrieval index, commit and push each clean iteration. |

## Per-Iteration Notes

- 2026-07-21T20:58:30Z: V54 block started from clean, synchronized
  `main` at `5d538329`. The initial backlog prioritizes a semantic inventory
  before any stage claim so cross-sectional/source-confounded data cannot be
  misread as evidence about progression.
- 2026-07-21T21:02:06Z: Resumed immediately after a health-check interruption.
  The OpenGWAS POST-only check completed successfully (HTTP 200); no idle gap
  was charged to active time.
- 2026-07-21T21:05:04Z: Progression semantic inventory completed over seven
  held datasets/packages. Two bounded questions are executable; four decisive
  questions are blocked or non-identifiable. The first real-data test is a
  source-overlap-restricted PPMS-versus-SPMS module comparison, not a
  transition, progression-rate, or treatment-benefit claim.
- 2026-07-21T21:05:04Z: Froze `PROGRESSION_STAGE_TEST_V54.md`. The design
  prevents source/tissue mixing, uses only five pre-existing modules, and
  requires cross-source directional agreement plus HC3, permutation, BH, and
  max-T gates.
- 2026-07-21T21:07:04Z: Iteration 1 ready for commit: inventory, semantic
  contract, cumulative report, and frozen stage-test plan pass provenance,
  structural, syntax, whitespace, and size/path guards. Active time accrued
  through this checkpoint: 0h08m34s; the resumed interval remains open.
- 2026-07-21T21:10:15Z: Completed the frozen source/tissue-balanced stage
  test on 44 donors with 300,000 three-seed nulls. No module passed. CD44/CXCR4
  and IFN/APC were same-direction across Amsterdam and UK but statistically
  inconclusive; HLA, MIF, and lysosomal effects were direction-discordant. No
  progression, target, or therapeutic claim was upgraded.
- 2026-07-21T21:17:30Z: Completed the frozen two-dataset lesion-state test.
  No module passed the orthogonal-context gate. CD44/CXCR4 was positive in all
  three active/inactive pairs but null in the 21-donor morphology cohort;
  lysosomal state passed the morphology family-wise gate but was not consistent
  across active-edge donors. The isolated lysosomal result is queued for a
  composition-specificity sensitivity and is not a progression or target lead.
- 2026-07-21T21:18:29Z: Iteration 3 ready for verification and commit. Active
  time accrued through this checkpoint: 0h19m59s; the resumed interval remains
  open.
- 2026-07-21T21:22:27Z: The frozen post-result lysosomal morphology
  specificity audit completed. Its fully adjusted association survived 300,000
  donor-wild nulls, max-variant correction, three-seed stability, and all 21
  leave-one-donor fits. It remains strictly bounded to foamy morphology because
  the adjustments are transcript-state proxies and the chronic-active-edge
  dataset did not supply directional replication. Active time accrued through
  this checkpoint: 0h23m57s; the resumed interval remains open.
- 2026-07-21T21:24:47Z: Froze the transition-identifiability contract before
  execution. A valid transition dataset must link repeated transcriptomes,
  time-varying subtype/conversion status, repeated disability or adjudicated
  conversion, and treatment context to a verified subject ID. Relapse,
  pregnancy, pharmacodynamic, and same-death lesion repeats fail closed rather
  than serving as progression surrogates. Active time accrued: 0h26m17s.
- 2026-07-21T21:28:02Z: Executed the transition-identifiability gate over
  seven held datasets. Five have verified subject maps and two have repeated
  transcriptomes, but none measures time-varying stage or repeated disability/
  adjudicated conversion. GSE24427's two-year relapse follow-up is explicitly
  not substituted for disability progression. Active time accrued: 0h29m32s.
- 2026-07-21T21:31:02Z: Froze a second, non-overlapping progression-lesion
  family using only pre-existing project modules: OXPHOS, resolution/
  efferocytosis proxy, NRF2 antioxidant response, stress/cytotoxicity, and the
  signed MOCCI switch. Iron and senescence remain untested rather than receiving
  post hoc signatures. Active time accrued: 0h32m32s.
- 2026-07-21T21:34:50Z: Completed the five-module lesion panel. No module
  transferred through the orthogonal-context gate. A family-wise-significant
  OXPHOS decrease in foamy morphology reverses the majority chronic-active
  direction and remains morphology-bounded; resolution/efferocytosis and MOCCI
  are concordant but inconclusive. Active time accrued: 0h36m20s.
- 2026-07-21T21:37:04Z: Froze the post-result OXPHOS/lysosomal mutual-
  adjustment sensitivity. Two disjoint scores, two corrected endpoints,
  300,000 donor-wild nulls, and LODO stability will test separability without
  upgrading either morphology association. Active time accrued: 0h38m34s.
- 2026-07-21T21:39:15Z: Mutual adjustment retained 90.2% of the OXPHOS
  coefficient and 89.7% of the lysosomal coefficient; both pass the corrected
  donor-wild and LODO gates. This is a two-feature foamy transcript state in one
  cohort, not progression or intervention evidence. Active time accrued:
  0h40m45s.
- 2026-07-21T21:43:28Z: The frozen CNS-versus-peripheral eligibility audit
  found zero valid compartment pairs. GSE228330 baseline has 10 RRMS and 5 SPMS
  samples, with subtype/activity imbalance (Fisher `p=0.01698`) and no verified
  subject map, processed matrix, batch/composition fields, or disability
  trajectory. No peripheral expression test was run; the result is an
  identifiability boundary, not a biological null. Active time accrued:
  0h44m58s.
- 2026-07-21T21:47:09Z: Completed the frozen intervention-direction map over
  nine pre-existing states. Zero passes the first progression-specific gate;
  held V53 perturbations add zero replicated selective control nodes, zero
  corrected additive-pair passes, and zero consensus causal orientations.
  AlphaFold context is ineligible and was not used. Active time accrued:
  0h48m39s.
- 2026-07-21T21:50:28Z: The frozen lesion-stratum transport sensitivity found
  no corrected transport of either foamy-state endpoint across eligible classes
  2 and 3. OXPHOS retained its negative direction but was imprecise; lysosomal
  direction reversed in class 2. NAWM was ineligible with four foamy donors.
  This narrows the pooled morphology result without claiming a subgroup null.
  Active time accrued: 0h51m58s.
- 2026-07-21T21:53:58Z: A direct two-endpoint morphology-by-lesion interaction
  test found no supported heterogeneity (OXPHOS max-family `p=0.940`;
  lysosomal `p=1.000`; both LODO signs unstable). This avoids comparing
  subgroup p-values but does not establish homogeneity because intervals are
  wide. The pooled morphology state remains context-bounded and unresolved.
  Active time accrued: 0h55m28s.
- 2026-07-21T21:56:37Z: Completed the exact progression-cohort acquisition
  contract. It separates longitudinal disability/PIRA, paired-compartment, and
  functional-direction roles and defines 64 unique required fields with
  fail-closed actions. It explicitly forbids relapse, stage, morphology, or
  pharmacodynamics from substituting for disability progression. Active time
  accrued: 0h58m07s.
- 2026-07-21T21:58:21Z: Completed a ready-unsent GSE228330 progression-metadata
  addendum and 29-field return schema. It requests the exact fields blocking
  pairing, subtype interpretation, progression, composition, and batch control;
  the cohort remains pharmacodynamic context unless the returned package passes
  the new role gate. Active time accrued: 0h59m51s.
- 2026-07-21T22:00:52Z: Implemented the progression-package inventory gate and
  verified six clearly labeled synthetic fixtures. Complete P1/P2/P3 inventories
  pass; missing outcome, pairing/composition/batch, or progression-prequalified
  functional fields fail closed. A pass is intake readiness only. Active time
  accrued: 1h02m22s.
- 2026-07-21T22:03:56Z: Completed a 288,000-cohort, three-seed synthetic
  progression-event power grid. Null FPR was calibrated (median `0.043`, maximum
  `0.060`). Only 7/24 non-null scenarios reached 80%; assumed OR 1.25/1.5 did
  not by `n=240`. This is method-design evidence only, not an empirical MS
  effect or universal N target. Active time accrued: 1h05m26s.
- 2026-07-21T22:10:32Z: Claude and Gemini independently returned six
  progression-method objections each. Their outputs were segregated as
  proposal-only external records. Multi-lineage agreement prioritizes
  the Macnair source-by-stage interaction; Claude also identified a substantive
  family-definition issue across the sequential morphology follow-ups. Both
  audits were frozen before execution. Active time accrued: 1h12m02s.
- 2026-07-21T22:16:23Z: Grounded the two priority review checks. No Macnair
  source-by-stage interaction passed the frozen five-module gate. The complete
  12-test post-result morphology family produced a substantive downgrade: the
  required fully adjusted lysosomal endpoint (Holm `p=0.0861`) and both
  mutually adjusted endpoints (each `p=0.0960`) fail global family control.
  Their coefficients remain descriptive, but V54 now labels them exploratory
  post-result morphology associations. Active time accrued: 1h17m53s.
- 2026-07-21T22:21:52Z: Replaced Gemini's invalid repeated-sample Fisher
  proposal with a frozen donor-estimand audit. Only 6/21 donors and 3/43
  donor-by-lesion blocks contain both morphology labels. In the six informative
  donors, OXPHOS retained direction but was null and LODO-unstable; lysosomal
  reversed near zero. The pooled morphology coefficients are substantially
  between-donor or unresolved. Active time accrued: 1h23m22s.
- 2026-07-21T22:25:22Z: Closed both simulation objections. The default null
  grid is acceptably calibrated: the 0.060 maximum is 90/1,500 (Wilson
  `0.049-0.073`), no cell's lower bound exceeds 0.05, and the 48-cell
  binomial-reference max-tail is `0.895`. A further 576,000 synthetic cohorts
  show material sensitivity to outcome error: 80%-passing scenarios decline
  from 7/24 to 4/24 at 5% and 3/24 at 10%. No rate is presented as an empirical
  MS or PIRA estimate. Active time accrued: 1h26m52s.
- 2026-07-21T22:28:14Z: Closed all 12 Claude/Gemini objections with an
  artifact-traced disposition table. Two concerns held strongly enough to
  change evidential grade, both narrowing the foamy morphology state; none
  changed a progression or target verdict. The independent review therefore
  added value through a substantive downgrade rather than a new positive lead.
  Model spend remains unavailable from the current AI Core response path.
  Active time accrued: 1h29m44s.
- 2026-07-21T22:33:22Z: Completed the blinded P1/P2 process contract and
  endpoint semantic gate. Three valid synthetic disability declarations pass;
  nine relapse/stage/morphology/pharmacodynamic proxy, incomplete,
  unconfirmed, interaction-free, or unblinded declarations fail closed. This
  is method behavior only and leaves no new progression claim. Active time
  accrued: 1h34m52s.
- 2026-07-21T22:36:49Z: Expanded the progression intake regression to 14
  synthetic fixtures. A new nonexistent-path case exposed a real validator
  defect: the issue was logged but did not enter the pass boolean. The logic is
  fixed, and duplicate, unknown-additive, unknown-substitution, missing-path,
  unverified, zero-nonmissing, and missing-column behavior now passes its
  permanent regression. Active time accrued: 1h38m19s.
- 2026-07-21T22:44:03Z: Completed the frozen 90,000-cohort progression
  event-time design with 180,000 route evaluations. The source/treatment-
  stratified null is compatible with nominal calibration (median 0.046,
  maximum 0.0653; 40-cell reference max-tail 0.776), while deliberate
  confounding inflates the unadjusted null median to 0.0887 and maximum to
  0.1907. Four PHReg numerical reference fixtures pass to 2.67e-15. This is
  synthetic method behavior only. Active time accrued: 1h45m33s.
- 2026-07-21T22:48:18Z: Completed an artifact-checked 18-item progression
  delta against V37. Twelve historical items retain their original relevance/
  novelty scores and are classified only for V54 scope; six post-V37 items are
  added without invented scores. No item becomes progression evidence or a
  target. Active time accrued: 1h49m48s.
- 2026-07-21T22:50:35Z: Combined inventory and endpoint semantics into one
  fail-closed intake decision. Nine synthetic fixtures bind package ID, role,
  endpoint, synthetic status, and score blindness; valid P1/P2 plus additive
  metadata pass, while every component or cross-gate mismatch fails. Active
  time accrued: 1h52m05s.
- 2026-07-21T22:52:30Z: Froze the P2 compartment-interaction power plan before
  simulation. It requires a direct paired or unpaired interaction, varies
  compartment correlation and composition imbalance/reliability, and forbids
  difference-of-significance localization. Active time accrued: 1h54m00s.
- 2026-07-21T22:57:28Z: Completed 288,000 unique synthetic P2 cohorts and
  576,000 direct-interaction route evaluations. Calibrated regimes reached the
  frozen 80% threshold in 27/36 non-null scenarios. Noisy composition
  adjustment under true imbalance was anti-conservative (null maximum
  `0.2227`) and is excluded from power interpretation; unadjusted imbalance was
  worse (maximum `0.5827`). Four independent `statsmodels` OLS fixtures pass
  to `2.22e-15`. Active time accrued: 1h58m58s.
- 2026-07-21T22:59:53Z: Froze the event-time assumption audit before
  simulation. It distinguishes proportional, early-only, late-only, and
  crossing effects and five censoring mechanisms, including a deliberately
  non-independent joint score/event-risk mechanism. Window-specific tests are
  diagnostic only and cannot replace the frozen whole-follow-up Cox route.
  Active time accrued: 2h01m23s.
- 2026-07-21T23:09:01Z: Completed 225,000 synthetic event-time cohorts and
  675,000 whole/early/late evaluations. Administrative, independent,
  score-dependent, and event-risk-only censoring pass the whole-follow-up null
  rule. Joint score/event-risk censoring is strongly anti-conservative (null
  median `0.544`, maximum `0.795`, all significant calls spurious-negative).
  Crossing effects are largely canceled in one coefficient despite opposite
  window signs. Four scalar/probability/PHReg reference checks pass to
  `2.94e-15`. Active time accrued: 2h10m31s.
- 2026-07-21T23:12:48Z: Converted the event-time failures into an additive,
  blinded receipt gate without editing the frozen P1/P2 pre-registration.
  Administrative-only and documented nonadministrative fixtures route as
  specified; unknown/outcome-related loss, missing dates or diagnostics,
  unblinding, and window-p-value substitution fail closed. All eight synthetic
  fixtures pass expected behavior. Active time accrued: 2h14m18s.
- 2026-07-21T23:13:52Z: Froze the synthetic CDP/PIRA adjudication regression
  before implementation. Ten edge-case families have predetermined decisions,
  including transient or discordant worsening, relapse/steroid exclusion,
  missing or mistimed confirmation, censoring before confirmation, and invalid
  baseline. Active time accrued: 2h15m22s.
- 2026-07-21T23:16:19Z: Implemented the parameterized endpoint processor and
  completed 11/11 synthetic regressions. A fixture-marker boolean identity bug
  was exposed and fixed before commit. Confirmed CDP is retained where the same
  worsening is PIRA-excluded by relapse; missing/mistimed confirmation and
  pre-confirmation censoring remain inconclusive rather than negative. Active
  time accrued: 2h17m49s.
- 2026-07-21T23:18:09Z: Implemented the P2 composition-method acceptance gate.
  Direct linked flow/CyTOF/CITE-seq/single-cell counts are eligible for
  cohort-specific calibration; proxies require a blinded direct-reference
  subset and an empirical null-calibration pass and remain sensitivity-only.
  Expression-derived proxies, missing linkage, outcome selection, and
  unresolved missingness fail. All 9 synthetic fixtures pass. Active time
  accrued: 2h19m39s.
- 2026-07-21T23:20:36Z: Completed the metadata-only candidate role matrix over
  ten known cohorts/routes, verifying five unique source artifacts. Zero
  qualifies for P1, P2, or P3. Gafson/Karolinska remain monitoring-validation
  routes, GSE24427 remains relapse/pharmacodynamic context despite repeated
  expression, and all held brain cohorts remain cross-sectional/pathology
  context. No expression values or quarantined package was read. Active time
  accrued: 2h22m06s.
- 2026-07-21T23:30:11Z: Completed the consolidated V54 regression command. Its
  first run exposed a virtualenv symlink-resolution defect that dropped
  NumPy/Pandas in child processes; preserving `sys.executable` fixed it. The
  final run passes 16/16 executable checks and 28/28 artifact/claim invariants,
  including zero supported stage modules, zero transition-identifiable
  datasets, zero target revisits, retained morphology downgrades, 0/10 role
  eligibility, numerical references, both provenance gates, and repository
  guards. Active time accrued: 2h31m41s.
- 2026-07-21T23:31:53Z: Refilled the executable backlog and froze the
  competing-risk audit before simulation. It separates independent,
  score-dependent, progression-frailty-dependent, and deliberately joint
  score/frailty death while retaining the cause-specific Cox route. A death
  composite is explicitly not substituted post hoc. Active time accrued:
  2h33m23s.
- 2026-07-21T23:36:39Z: Completed 129,600 seeded synthetic competing-risk
  cohorts. Score-only and progression-risk-only death calibrated; independent
  death triggered the strict single-cell rule but was compatible with the
  predeclared family-maximum reference and is therefore excluded from power as
  inconclusive, not called biased. Joint score/progression-risk death was
  invalid (null maximum `0.119`, predominantly false protective). Four of ten
  calibrated non-null scenarios reached 80% power. Active time accrued:
  2h38m09s.
- 2026-07-21T23:39:49Z: Competing-risk artifacts were integrated into the
  cumulative report and pinned by three new regression invariants. Final
  verification exposed and fixed generated-TSV trailing tabs that occurred
  after the suite's internal whitespace check; the regenerated suite now
  passes 16/16 commands and 31/31 invariants, with provenance, structure, and
  repository guards passing. Active time accrued: 2h41m19s.
- 2026-07-21T23:41:26Z: Froze the visit-schedule/interval-observation audit
  before simulation. The design uses a two-year irreversible latent endpoint,
  quarterly/semiannual/annual visits, mandatory later confirmation, complete,
  independent, score-dependent, and joint score/risk attendance, plus fixed
  detection-time and midpoint routes. A Breslow tie-aware implementation must
  pass an independent PHReg reference. Active time accrued: 2h42m56s.
- 2026-07-21T23:46:55Z: Completed 172,800 seeded visit-schedule cohorts and
  691,200 route evaluations. Complete and independently missed visits
  calibrated; score-dependent and joint score/progression-risk attendance
  invalidated both observed routes with predominantly false protective calls
  (null maxima `0.158` and `0.165`). Only complete quarterly observation at
  event probability `0.30` reached 80% by `n=320`; annual complete observation
  retained 51/86 median latent events and power `0.592`, while 20% independent
  missingness retained 33/86 and power `0.399`. The tied-time implementation
  matches PHReg to `3.55e-15`. Active time accrued: 2h48m25s.
- 2026-07-21T23:48:19Z: Integrated the visit-schedule boundary and pinned it
  in the consolidated suite. All 17 command checks and 35 artifact invariants
  pass, as do provenance, structural, whitespace, tracked-size, and temporary-
  path guards. Active time accrued: 2h49m49s.
- 2026-07-21T23:49:12Z: Froze the repeated molecular-score reliability design
  before simulation. One, two, and three baseline measurements are compared at
  starting reliability `0.40/0.70`, independent or `0.50`-correlated error,
  10% per-measurement missingness, two event rates, two non-null HRs, and three
  sample sizes. Material utility requires at least 0.10 absolute power gain
  over one measurement in aggregate and every seed. Active time accrued:
  2h50m42s.
- 2026-07-21T23:52:24Z: Completed 216,000 seeded repeated-measurement cohorts.
  Six of ten reliability/measurement/error plans pass strict null calibration;
  four have isolated strict-cell but family-compatible flags and zero are
  directionally invalid. Sixteen of 96 repeat-gain cells meet the frozen
  aggregate and every-seed 0.10 rule, all from starting reliability `0.40`.
  At `n=320`, event probability `0.30`, and synthetic HR `1.7`, power rises
  `0.578 -> 0.781 -> 0.847` for one, two, and three independent-error measures;
  0.50-correlated error limits the three-measure plan to `0.748`. Active time
  accrued: 2h53m54s.
- 2026-07-21T23:53:47Z: Integrated the conditional repeat-measurement result
  and pinned cohort count, zero invalid plans, 16 material cells, and the
  bounded verdict. The consolidated suite passes 17/17 commands and 39/39
  invariants; provenance, structure, whitespace, size, and path guards pass.
  Active time accrued: 2h55m17s.
- 2026-07-21T23:54:43Z: Froze the three-site progression transportability
  audit. The design deliberately aligns site score means with baseline hazards
  in one family, contrasts balanced and 60/30/10 allocation, and requires a
  positive site-stratified result, same-direction site estimates, all leave-
  site-out tests, adequate events, and no heterogeneity. Site-only and reversed
  effects are negative controls for false transport. Active time accrued:
  2h56m13s.
- 2026-07-21T23:57:59Z: Completed 115,200 seeded three-site cohorts. Pooled
  null rejection reaches `0.685/0.482` when site score means align with baseline
  hazards; all four site-stratified null families calibrate. Only two of 24
  designs pass full transport: `n=450`, event probability `0.30`, balanced site
  allocation, under either score structure (transport `0.801/0.817`, every-seed
  minima `0.787/0.785`). Corresponding 60/30/10 designs reach only
  `0.758/0.748`. Negative-control false transport remains at most `0.0225` and
  `0.0333`; PHReg references pass to `2.56e-13`. Active time accrued:
  2h59m29s.
- 2026-07-21T23:59:11Z: Integrated and regression-pinned the site-confounding
  and transport boundary. All 18 command checks and 44 artifact invariants
  pass, as do provenance, structural, whitespace, tracked-size, and temporary-
  path guards. Active time accrued: 3h00m41s.
- 2026-07-22T00:01:34Z: Completed the prospective progression design synthesis.
  Sixteen machine-readable requirements trace 14 committed artifacts. The
  reference design is `n=450`, three balanced sites, a 30% event setting,
  quarterly observation, and median minimum 26 site events in the only passing
  transport cells; every number is explicitly assumption-labeled, not a
  guaranteed minimum. Zero known P1-eligible cohorts remains the operational
  blocker. Active time accrued: 3h03m04s.
- 2026-07-22T00:02:57Z: The design synthesis now runs inside the consolidated
  regression suite. All 19 command checks and 48 artifact invariants pass,
  together with provenance, structure, whitespace, size, and path guards.
  Active time accrued: 3h04m27s.
- 2026-07-22T00:04:31Z: Expanded the endpoint adjudicator to 16/16 synthetic
  regressions. Duplicate dates, malformed component/day values, and unknown
  endpoints return explicit `INVALID_INPUT` rather than crashing or becoming
  false negatives. The frozen candidate search correctly skips an onset at day
  30 that fails confirmation and returns the later valid onset/confirmation at
  days 300/480. Active time accrued: 3h06m01s.
- 2026-07-22T00:05:28Z: Endpoint hardening is pinned in the suite; 19/19
  command checks and 49/49 invariants pass with all provenance, structural,
  whitespace, size, and path guards. Active time accrued: 3h06m58s.
- 2026-07-22T00:06:17Z: Refilled the backlog with six internally executable
  progression-design tasks and froze the site-score harmonization audit. It
  compares global with outcome-blind within-site scaling across three assay-
  scale patterns and retains the full transport and reversed-effect controls.
  Active time accrued: 3h07m47s.
- 2026-07-22T00:10:49Z: Completed 129,600 site-scale cohorts and 259,200
  transport-route evaluations. No null family is invalid; two within-site
  families have strict-cell but family-compatible flags and remain excluded.
  Six of 36 comparisons meet the material-gain rule, all under severe
  `0.5/1.0/2.0` scale mismatch. In the balanced `n=450`, event-0.30 design,
  blinded within-site scaling raises transport `0.466 -> 0.809`; the imbalanced
  counterpart reaches `0.755` and remains not ready. Reversed-effect false
  transport is at most `0.0325`. Active time accrued: 3h12m19s.
- 2026-07-22T00:12:11Z: Integrated and pinned the harmonization boundary. The
  consolidated suite passes 19/19 commands and 53/53 invariants; provenance,
  structure, whitespace, tracked-size, and temporary-path guards pass. Active
  time accrued: 3h13m41s.
- 2026-07-22T00:15:18Z: Froze the site-score calibration receipt-gate
  contract before implementation. Unknown site or assay-scale mappings fail
  closed; documented scale differences require a pre-frozen, outcome-blind
  within-site transform; every multisite route remains site-stratified; and
  site imbalance remains outside the tested balanced transport reference.
  Active time accrued: 3h16m48s.
- 2026-07-22T00:18:55Z: Completed the site-score calibration receipt gate.
  All 10 synthetic declarations match their frozen decisions; six unsafe
  routes fail closed, while the valid imbalanced route carries an explicit
  outside-reference warning. The consolidated suite passes 20/20 commands and
  55/55 invariants. Active time accrued: 3h20m25s.
- 2026-07-22T00:20:10Z: Froze the enrollment-inflation audit before
  simulation. It requires 90% assurance in every seed for 450 analyzable
  participants, 135 confirmed events, and per-site 150-analyzable/10-event
  floors under equal site quotas. Passive recruitment imbalance is audited
  separately and cannot earn transport readiness by brute-force enrollment.
  Active time accrued: 3h21m40s.
- 2026-07-22T00:23:59Z: Completed 122,805,000 seeded enrollment-planning
  replicates. The conditional equal-quota gross totals are 690 under 10% loss
  in each channel/event probability 0.30, 990 under 20% losses/event 0.30, and
  1,380 under 10% losses/event 0.15. Passive 60/30/10 recruitment needs about
  2,055 merely to clear arithmetic floors and remains outside the transport
  reference. The suite passes 20/20 commands and 60/60 invariants. Active time
  accrued: 3h25m29s.
- 2026-07-22T00:25:28Z: Froze the blinded feasibility-calculator contract.
  It consumes actual combined-intake, event-time, and site-score gate summaries
  with matching package IDs plus blinded aggregate design metadata. Invalid
  gates or prior score/outcome access fail closed; valid designs below the
  synthetic reference are routed to cohort-specific reparameterization rather
  than called negative. Active time accrued: 3h26m58s.
- 2026-07-22T00:27:13Z: Completed the blinded feasibility calculator. All nine
  synthetic packages match expected routes: two reference-aligned, four valid
  but below reference, and three fail closed. A mismatched upstream package ID
  is rejected even when every copied decision says pass. Active time accrued:
  3h28m43s.
- 2026-07-22T00:29:05Z: Integrated feasibility routing into the consolidated
  suite; all 21 commands and 62 invariants pass. Active time accrued:
  3h30m35s.
- 2026-07-22T00:29:59Z: Froze the blinded information-accrual monitor. It may
  read only aggregate enrollment, analyzable, site, visit, confirmation, and
  censoring counts. Any effect direction, score association, p-value, or
  individual outcome input fails closed; the monitor has no efficacy-stopping
  authority. Active time accrued: 3h31m29s.
- 2026-07-22T00:31:51Z: Completed the aggregate information monitor. All ten
  synthetic routes match expectation: three continue, one holds, one locks at
  reference information, and five fail closed. The first run correctly caught
  an impossible fixture count (`analyzable > enrolled`); the fixture was fixed,
  not the guard weakened. Active time accrued: 3h33m21s.
- 2026-07-22T00:32:47Z: Integrated the monitor; the consolidated suite passes
  22/22 commands and 65/65 invariants. Active time accrued: 3h34m17s.
- 2026-07-22T00:34:12Z: Froze the treatment-switch estimand audit before
  simulation. Treatment-policy and censor-at-switch routes are reported side
  by side across no, independent, score-dependent, progression-risk-dependent,
  and joint switching with protective/neutral/harmful post-switch effects. No
  post-result estimand selection is allowed. Active time accrued: 3h35m42s.
- 2026-07-22T00:37:29Z: Completed 72,000 treatment-switch cohorts and 144,000
  route evaluations. Three null families are invalid: both estimands under
  joint score/risk switching and treatment policy under score-dependent
  switching. Two independent families have strict-cell but family-compatible
  flags and are excluded. The initial code overcalled those two by omitting the
  fixed family-maximum adjudication; that inconsistency was corrected and
  documented before commit. Active time accrued: 3h38m59s.
- 2026-07-22T00:39:09Z: Integrated the switch-estimand boundary; the
  consolidated suite passes 22/22 commands and 69/69 invariants. Active time
  accrued: 3h40m39s.
- 2026-07-22T00:40:26Z: Froze the linear-effect misspecification audit before
  simulation. Null, linear, high-threshold, monotone-saturation, U-shaped, and
  inverted-U risks are tested with one primary linear coefficient plus fixed
  threshold, saturated-score, and linear-quadratic diagnostics. Diagnostic
  multiplicity is controlled and cannot replace the primary after inspection.
  Active time accrued: 3h41m56s.
- 2026-07-22T00:47:34Z: Completed the nonlinear audit after two explicit null-
  control repairs. The asymptotic run failed 4/5 null families; a disjoint
  18,000-cohort calibration bank was added, then evaluation expanded from 800
  to 3,000/seed when its first primary null remained unstable. In the final
  108,000 evaluation cohorts, 0/5 null families are invalid. Only U-shaped
  crossing risk at n=320 meets the frozen material-miss rule (linear 0.105,
  corrected omnibus 0.891, minimum-seed gain 0.779). This is a synthetic design
  warning, not an MS risk-shape finding. Active time accrued: 3h49m04s.
- 2026-07-22T00:49:08Z: Integrated and pinned the nonlinear boundary; the
  consolidated suite passes 22/22 commands and 74/74 invariants. Active time
  accrued: 3h50m38s.
- 2026-07-22T00:50:03Z: Refilled the internally executable backlog after the
  seeded analyses completed. Froze the treatment-switch receipt gate first: a
  cohort must declare one primary and the opposite frozen sensitivity, retain
  complete switch dates/reasons/treatment context, and prohibit post-result
  estimand choice. Active time accrued: 3h51m33s.
- 2026-07-22T00:51:13Z: Completed the treatment-switch receipt gate. All ten
  synthetic declarations match expectation: complete switch/no-switch plans
  pass, while eight incomplete, unblinded, or post-result-selectable plans fail
  closed. Active time accrued: 3h52m43s.
- 2026-07-22T00:52:50Z: Integrated the treatment-switch receipt gate; the
  consolidated suite passes 23/23 commands and 76/76 invariants. Active time
  accrued: 3h54m20s.
- 2026-07-22T00:54:02Z: Pushed the treatment-switch gate as `f5b0d028` and
  froze the nonlinear diagnostic receipt contract before implementation. The
  primary stays one linear coefficient; the exact threshold, saturation, and
  quadratic family is non-rescuing and multiplicity-controlled. Active time
  accrued: 3h55m32s.
- 2026-07-22T00:55:18Z: Completed the nonlinear diagnostic receipt gate. Both
  fixed correction routes pass, while eight changed, unblinded, rescuing, or
  invalid-calibration declarations fail closed as expected. Active time
  accrued: 3h56m48s.
- 2026-07-22T00:57:19Z: Integrated the nonlinear diagnostic receipt gate; the
  consolidated suite passes 24/24 commands and 78/78 invariants. Active time
  accrued: 3h58m49s.
- 2026-07-22T00:59:33Z: Completed the full synthetic P1 intake-to-lock dry run.
  The actual seven-stage validators bind one package: one route reaches lock,
  one continues blinded accrual, and eight stage or identity faults fail
  closed. Active time accrued: 4h01m03s.
- 2026-07-22T01:01:14Z: Integrated the intake-to-lock state machine; the
  consolidated suite passes 25/25 commands and 83/83 invariants. Active time
  accrued: 4h02m44s.
- 2026-07-22T01:04:27Z: Pushed the intake-to-lock composition as `22e06432`
  and froze the combined ascertainment audit before simulation. Ten clean,
  single-process, separable, weak-joint, and site-linked stacks will be tested
  under guarded and naive routes with family-level null adjudication. Active
  time accrued: 4h05m57s.
- 2026-07-22T01:07:15Z: The 288,000-cohort primary audit found one guarded
  compounded-invalidity family (`weak_joint_all`; max null 0.0617, family tail
  0.0363), while all three constituent families calibrated. Because the call
  is marginal and not uniformly elevated by seed, froze an independent-seed
  confirmation with the identical generator and guarded route before accepting
  it. Active time accrued: 4h08m45s.
- 2026-07-22T01:10:10Z: Independent 144,000-cohort confirmation did not retain
  the unique-compounding claim: attendance weak-joint alone is family-invalid
  (max 0.0570; family tail 0.0461), while the combined stack remains invalid
  (0.0640; lower CI 0.0581; family tail 5.82e-6). The honest boundary is joint
  score/risk attendance risk, not emergence only under stacking. Active time
  accrued: 4h11m40s.
- 2026-07-22T01:12:26Z: Integrated the primary and independent confirmation;
  the consolidated suite passes 25/25 commands and 92/92 invariants. Active
  time accrued: 4h13m56s.
- 2026-07-22T01:13:18Z: Pushed the ascertainment audit as `fdad631a` and began
  the machine-readable progression reference manifest. It will hash-bind all
  executable gate sources and freeze lifecycle decisions without changing any
  threshold. Active time accrued: 4h14m48s.
- 2026-07-22T01:14:24Z: Completed the machine-readable progression reference
  manifest. Eight gates and 18 source artifacts bind to contract digest
  `2223e534...`; current verification passes and a threshold-tampered copy
  fails. Active time accrued: 4h15m54s.
- 2026-07-22T01:16:04Z: Registered manifest verification in the consolidated
  suite; 26/26 commands and 97/97 invariants pass. Active time accrued:
  4h17m34s.
- 2026-07-22T01:17:13Z: Pushed the reference manifest as `25355680` and froze
  an acquisition value-of-information synthesis. Ranking is dependency- and
  gate-based, not a fabricated probability of biological success. Active time
  accrued: 4h18m43s.
- 2026-07-22T01:18:41Z: Completed the acquisition value-of-information
  synthesis. Nine bundles validate against committed fields/gates/artifacts;
  the P1 longitudinal link and ascertainment provenance rank first, while P2
  and P3 remain conditional. Active time accrued: 4h20m11s.
- 2026-07-22T01:19:56Z: Registered acquisition synthesis in the consolidated
  suite; 27/27 commands and 103/103 invariants pass. Active time accrued:
  4h21m26s.
- 2026-07-22T01:21:28Z: Pushed acquisition ranking as `91f261bc`, refilled the
  executable backlog, and froze a site-aware weaker-effect cohort-size
  extension through n=1,500. Active time accrued: 4h22m58s.
- 2026-07-22T01:23:08Z: Completed the 90,000-cohort weaker-effect extension.
  The guarded null calibrates. HR 1.2 does not reach the rule by n=1,500; HR
  1.3 needs 900 analyzable at 30% events or 1,500 at 15%; HR 1.5 needs 450 or
  600. These are conditional latent-effect assumptions only. Active time
  accrued: 4h24m38s.
- 2026-07-22T01:27:58Z: The first suite integration exposed decimal scenario
  keys incompatible with dotted invariant paths. Replaced labels with stable
  integer-coded keys, reran all 90,000 cohorts unchanged, and confirmed 27/27
  commands plus 111/111 invariants pass. Active time accrued: 4h29m28s.
- 2026-07-22T01:29:01Z: Pushed weaker-effect planning as `ad9141d2` and froze
  endpoint-confirmation error sensitivity before simulation. Null validity is
  adjudicated before any power comparison. Active time accrued: 4h30m31s.
- 2026-07-22T01:35:33Z: Completed 230,400 endpoint-confirmation cohorts. A
  pandas `stack` method/column collision surfaced only after generation, was
  fixed without changing the frozen design, and the full run was repeated.
  Four score-linked or joint null families are invalid; four independent or
  risk-only families calibrate. Active time accrued: 4h37m03s.
- 2026-07-22T01:40:17Z: Integrated the confirmation-error boundary and its
  machine summary; 27/27 commands and 120/120 artifact invariants pass. Active
  time accrued: 4h41m47s.
- 2026-07-22T01:42:02Z: Pushed endpoint-confirmation audit as `726c35ba` and
  froze a leave-site-out precision extension. Unlike the existing sign gate,
  it requires each site's and each retained-site pair's one-step 95% interval
  to exclude zero before a design can be precision-ready. Active time accrued:
  4h43m32s.
- 2026-07-22T01:44:41Z: Completed 96,000 precision cohorts. Both null families
  calibrate and context-control false precision is 0.00083, but no design
  reaches readiness. The best HR1.5 n1,500/30%/balanced cell is 0.740 aggregate
  and 0.735 minimum-seed despite sign transport 0.950. Active time accrued:
  4h46m11s.
- 2026-07-22T01:47:43Z: Integrated the strict precision null and near-boundary
  result; 27/27 commands and 127/127 invariants pass. Active time accrued:
  4h49m13s.
- 2026-07-22T01:48:40Z: Pushed the first precision grid as `03147bb4` and
  separately froze an upper-range n1,800/2,100/3,000 extension before running
  it. The completed n<=1,500 grid is not retroactively expanded. Active time
  accrued: 4h50m10s.
- 2026-07-22T01:50:20Z: Completed the separately frozen 72,000-cohort
  extension. Under HR1.5/30%-event assumptions, balanced n1,800 is the first
  strict pass; 60/30/10 allocation needs n3,000. HR1.3 and 15%-event designs
  remain below the rule through n3,000. Active time accrued: 4h51m50s.
- 2026-07-22T01:51:35Z: Integrated the conditional upper-range boundary;
  27/27 commands and 134/134 invariants pass. Active time accrued: 4h53m05s.
- 2026-07-22T01:53:08Z: Pushed the upper-range precision result as `2ad705bd`
  and started a machine-validated P1 acquisition request packet. The packet
  requests provenance exposed by the confirmation audit without assuming any
  field was collected. Active time accrued: 4h54m38s.
- 2026-07-22T01:54:50Z: Completed the machine-validated acquisition packet.
  The 66-field response template covers all five immediate VOI bundles and
  keeps supplied/not-collected/not-shareable/unknown explicit; 51 gate-critical
  fields appear first. Active time accrued: 4h56m20s.
- 2026-07-22T01:56:26Z: Registered the request-packet builder; 28/28 commands
  and 141/141 invariants pass. Active time accrued: 4h57m56s.
- 2026-07-22T01:58:06Z: Pushed the acquisition packet as `33004bc7` and froze
  a seven-control, non-rescuing P1 diagnostic family. Each control has an exact
  fail-closed or specificity-downgrade action; clean controls cannot validate
  the primary result. Active time accrued: 4h59m36s.
- 2026-07-22T01:59:37Z: Completed the seven-control declaration gate. One exact
  synthetic family passes and nine malformed, post-access, rescuing, or
  action-altered declarations fail closed. Active time accrued: 5h01m07s.
- 2026-07-22T02:00:48Z: Registered the negative-control gate; 29/29 commands
  and 147/147 invariants pass. Active time accrued: 5h02m18s.
